Company Active PRIVATE-LIMITED-GUARANT-NSC

Company profile

Liverpool School of Tropical Medicine

Home | LSTM

Liverpool School of Tropical Medicine is a UK company with status active founded in 1905.

CRN
00083405
Founded
1905
Age
121

Overview

Legal name
LIVERPOOL SCHOOL OF TROPICAL MEDICINE
Region
Unknown
Registered address
PEMBROKE PLACE
LIVERPOOL 3
L3 5QA
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

Liverpool School of Tropical Medicine
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

15 events
30 Apr
2027

Accounts due

Accounts Due

Next accounts due date

22 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

08 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jul
2025

Accounts filed

Accounts

Last accounts made up date

04 Jan
1995

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction MTEyNjMwNjA0YWRpcXprY3g

Published 07 Jul 2026 04:32

02 Mar
1994

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction OTUyMDU2MzRhZGlxemtjeA

Published 07 Jul 2026 04:33

10 Feb
1993

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction MTQwMjAzMTk0YWRpcXprY3g

Published 07 Jul 2026 04:33

10 Jan
1992

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction MjkwNzAxNTFhZGlxemtjeA

Published 07 Jul 2026 04:32

05 Mar
1991

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction OTMwNzU1NTRhZGlxemtjeA

Published 07 Jul 2026 04:31

03 Jan
1990

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction MjA5OTk5NDlhZGlxemtjeA

Published 07 Jul 2026 04:31

16 Feb
1989

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction OTkzMjgwNzFhZGlxemtjeA

Published 07 Jul 2026 04:31

30 Dec
1987

Accounts With Accounts Type Full Group

Accounts Awaiting analysis

AA | Transaction OTkzMjg1OThhZGlxemtjeA

Published 07 Jul 2026 04:33

01 Jan
1987

Selection Of Documents Registered Before January 1987

Historical

PRE87 | Transaction MzQwMDU2NDQzMmFkaXF6a2N4 | Paper/PDF filed

Published 07 Jul 2026 04:32

29 Dec
1986

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction Mzk3NzA0MTJhZGlxemtjeA

Published 07 Jul 2026 04:33

30 Jan
1905

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2017
Funded years
2017, 2020, 2022
Age at first award
112 years

Projects

2022 Collaborative R&D

Optimisation of a novel series of SARS-CoV-2 inhibitors

1 Jul 2022 to 31 Oct 2023

Awarded
£335,291
Total cost £335,291

The COVID-19 pandemic is the most serious global health crisis in recent history with over 140,000 deaths in the UK and over 5 million deaths worldwide. Despite extensive vaccination programs, the virus remains transmissible with hospitalisation and mortality remaining high, both in the UK and globally. Infex Therapeutics, in partnership with the Universi...

2022 Collaborative R&D

Self-sanitising coatings to reduce healthcare associated infections

1 Jun 2022 to 30 Nov 2023

Awarded
£212,782
Total cost £212,782

Infections are so common that they are an ever-present risk to the public. Fighting such infections is becoming continually more difficult as the resistance to antibiotics increases. For example, Hospital Acquired Infections - HAIs - increase treatment times, and in extreme cases lead to the death of a patient (an estimated 3.5% of patients who acquire a ...

2022 Collaborative R&D

Development of a Novel Rapid Sepsis Point of Care Diagnostic Device

1 Feb 2022 to 31 Jul 2023

Awarded
£13,395
Total cost £13,395

More than 350,000 people suffer from sepsis in the UK annually, leading to 52,000 deaths. Rapid diagnosis is imperative to enable timely administration of interventional antibiotic treatment, however current methods are insufficient to empower clinicians to act within the critical first hour of admission. Early antibiotic therapy is vital to clinical outc...

2020 Collaborative R&D

Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19

1 Dec 2020 to 30 Nov 2021

Awarded
£47,802
Total cost £47,802

Society requires new solutions to reduce the probability of COVID-19 cross-infection as people resume their daily lives. However, common touch surfaces have been shown to contain significant viral and microbial contamination. The SARS-CoV-2 virus can be present on plastic and glass surfaces for several days and multiple users of the same touch surfaces cr...

2020 Collaborative R&D Lead participant

Delivering Integrated Solutions for Human Infections

1 Sep 2020 to 31 Aug 2025

Awarded
£12,160,451
Total cost £12,160,451
2017 Small Business Research Initiative Lead participant

Adjuvant free vaccines and companion diagnostics to control emerging flaviviruses

1 May 2017 to 31 May 2018

Awarded
£382,974
Total cost £382,974

Awaiting Public Project Summary

Product types

Collaborative R&D Small Business Research Initiative